Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

satraplatin

An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Orplatna
Code name:BMS-182751
BMY-45594
JM216
Chemical structure:(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum
(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search